Recent Updates
Recently added Catalysts
TNDM Negative Sentiment Score: 25/100

TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Tandem Diabetes Care, Inc. on behalf of long-term stockholders due to a class action complaint alleging fiduciary breaches. This complaint arises from misleading information regarding projected revenues for the year 2022. The firm's investigation focuses on potential misconduct by the board, particularly following a significant downward revision of revenue forecasts that led to a major drop in stock price. Investors have been urged to communicate with the firm regarding their rights and the ongoing investigation.

Market Sentiment Analysis

CONCERNS & RISKS

  • The investigation is a response to a class action complaint filed against Tandem Diabetes Care.
  • The company revised its 2022 revenue forecast downward, indicating operational challenges.
  • The stock price experienced a drastic decline of 30.4% following the negative guidance.

Full Press Release Details

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) on behalf of long-term stockholders following a class action complaint that was filed against Tandem on September 8, 2023 with a Class Period from August 3, 2022 to November 2, 2022. Our investigation concerns whether the board of directors of Tandem have breached their fiduciary duties to the company.
The complaint alleges that defendants provided investors with material information concerning Tandem’s projected revenue and sales for the year ending 2022. On August 2, 2022, Tandem estimated annual sales “to be in the range of $835 million to $845 million, which represents an annual growth of 19 percent to 20 percent compared to 2021.” Defendants provided these statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts.
According to the complaint, the truth emerged on November 2, 2022, when Tandem, in an investment call and Form 8-K filing, revised its 2022 forecast downward to $800 to $805 million. Reasons stated for the scale back included increased competition in the diabetes care sector, complications due to the COVID pandemic, and macroeconomic factors such as inflation. Investors and analysts reacted immediately to Tandem’s revised guidance. The price of Tandem’s common stock declined dramatically. On November 2, 2022, Tandem closed at $51.34; however, on November 3, 2022, Tandem closed at $35.72 – a one-day decline of 30.4%.
If you are a long-term stockholder of Tandem, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Tandem Diabetes Care

Frequently Asked Questions

What is Bragar Eagel & Squire, P.C. investigating?

They are investigating potential claims against Tandem Diabetes Care on behalf of long-term stockholders.

What triggered the investigation into Tandem Diabetes Care?

A class action complaint was filed on September 8, 2023, regarding fiduciary breaches.

What were Tandem’s initial sales projections for 2022?

Tandem projected annual sales between $835 million and $845 million for 2022.

What caused Tandem to revise its sales forecast?

The revision was due to competition, pandemic complications, and inflation.

How much did Tandem's stock decline after the forecast revision?

Tandem's stock fell by 30.4% from $51.34 to $35.72 in one day.

Last updated: Aug 10, 2024